Camila Cosmo, Amin Zandvakili, Nicholas J Petrosino, Yosef A Berlow, Noah S Philip
{"title":"Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: Recent Critical Advances in Patient Care.","authors":"Camila Cosmo, Amin Zandvakili, Nicholas J Petrosino, Yosef A Berlow, Noah S Philip","doi":"10.1007/s40501-021-00238-y","DOIUrl":"10.1007/s40501-021-00238-y","url":null,"abstract":"<p><strong>Purpose: </strong>Transcranial magnetic stimulation (TMS) is an evidence-based treatment for pharmacoresistant major depressive disorder (MDD). In the last decade, the field has seen significant advances in the understanding and use of this new technology. This review aims to describe the large, randomized controlled studies leading to the modern use of rTMS for MDD. It also includes a special section briefly discussing the use of these technologies during the COVID-19 pandemic.</p><p><strong>Recent findings: </strong>Several new approaches and technologies are emerging in this field, including novel approaches to reduce treatment time and potentially yield new approaches to optimize and maximize clinical outcomes. Of these, theta burst TMS now has evidence indicating it is non-inferior to standard TMS and provides significant advantages in administration. Recent studies also indicate that neuroimaging and related approaches may be able to improve TMS targeting methods and potentially identify those patients most likely to respond to stimulation.</p><p><strong>Summary: </strong>While new data is promising, significant research remains to be done to individualize and optimize TMS procedures. Emerging new approaches, such as accelerated TMS and advanced targeting methods, require additional replication and demonstration of real-world clinical utility. Cautious administration of TMS during the pandemic is possible with careful attention to safety procedures.</p>","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"8 2","pages":"47-63"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25481695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lisa M Najavits, H Westley Clark, Carlo C DiClemente, Marc N Potenza, Howard J Shaffer, James L Sorensen, Matthew T Tull, Allen Zweben, Joan E Zweben
{"title":"PTSD / substance use disorder comorbidity: Treatment options and public health needs.","authors":"Lisa M Najavits, H Westley Clark, Carlo C DiClemente, Marc N Potenza, Howard J Shaffer, James L Sorensen, Matthew T Tull, Allen Zweben, Joan E Zweben","doi":"10.1007/s40501-020-00234-8","DOIUrl":"10.1007/s40501-020-00234-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Posttraumatic stress disorder (PTSD) commonly co-occurs with substance use disorder (SUD) and is challenging to treat. We review all behavioral therapy models with at least one randomized controlled trial in a current PTSD/SUD population. We identify factors in selecting a model for clinical use, emphasizing a public health framework that balances the need for evidence with the need for feasibility in frontline settings.</p><p><strong>Recent findings: </strong>Seven published models and 6 unpublished models are reviewed. Public health considerations for choosing a model include: whether it's been studied across a broad range of SUDs and in complex SUD patients; whether it can be conducted in group modality; its appeal to patients and providers; its cost; workforce requirements; and its ability to reduce substance use in addition to PTSD.</p><p><strong>Summary: </strong>There are two broad types of models: those that originated in the PTSD field versus the SUD field. Overall, the latter are stronger on public health factors and more feasible in SUD settings. Published models in this category include Relapse Prevention, BRENDA, and Seeking Safety. PTSD/SUD research is at an early stage and there is a need for methodology that quantifies \"level of burden\" (patients' socioeconomic disadvantages) across trials.</p>","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 1","pages":"544-558"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41406071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacological Management of Neuropsychiatric Symptoms of Dementia.","authors":"Lauren B Gerlach, Helen C Kales","doi":"10.1007/s40501-020-00233-9","DOIUrl":"10.1007/s40501-020-00233-9","url":null,"abstract":"<p><strong>Purpose: </strong>Neuropsychiatric symptoms are universal across all stages and types of dementia and can cause significant challenges for patients and caregivers. While there are currently no approved medications for treatment of neuropsychiatric symptoms of dementia, a variety of psychotropic medications such as antipsychotics, benzodiazepines, anticonvulsants, and antidepressants are used off-label to treat these symptoms. This systematic review evaluated the available evidence for effectiveness and tolerability of pharmacologic treatments in addressing behavioral disturbances in dementia.</p><p><strong>Recent findings: </strong>Inclusion criteria were placebo-controlled, randomized controlled clinical trials (RCTs) or meta-analyses; a total of 38 studies and 3 meta-analyses representing an additional 27 RCTs met the inclusion criteria. Of the medication classes evaluated, atypical antipsychotics had the greatest available evidence for use, however, the treatment effect size was modest. Nine trials of antidepressants were included; 3 trials supported use in dementia. Eight trials of anticonvulsants were included; only one showed benefit. For benzodiazepines, 2 RCTs were included; only one trial of lorazepam showed improvement. Six trials of melatonin agonists were included; none showed efficacy outside of improved sleep measures. Evidence for effectiveness of pimavanserin and dextromethorphan-quinidine was limited to one study each, both of which showed benefit.</p><p><strong>Summary: </strong>Despite the widespread off-label use of psychotropic medications for treatment of neuropsychiatric symptoms in dementia, there are relatively few RCTs to evaluate their use with treatment effect sizes absent or modest for most medication classes. Of the medication classes reviewed, atypical antipsychotics have the best evidence for effectiveness, however, the overall magnitude of treatment effect is modest and must be balanced with risk of serious adverse events including death.</p>","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 4","pages":"489-507"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00233-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38733518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"POSITIVE PSYCHIATRY INTERVENTIONS IN GERIATRIC MENTAL HEALTH.","authors":"Jeffrey Lam, Awais Aftab, Ellen Lee, Dilip Jeste","doi":"10.1007/s40501-020-00228-6","DOIUrl":"10.1007/s40501-020-00228-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Positive psychiatry shifts the focus of geriatric mental healthcare beyond studying disorders and psychopathology to studying factors that contribute to mental well-being and successful aging. An increasing number of interventional studies are using treatments that target modifiable positive psychosocial characteristics (PPCs) and study their impact on mental health. Here we provide an overview of the literature on positive psychiatry interventions using illustrative examples of interventions targeting social connectedness, meaning in life, wisdom, and resilience.</p><p><strong>Recent findings: </strong>There is growing evidence that PPCs are modifiable constructs that may be associated with improved well-being, physical health, and mental health outcomes.</p><p><strong>Summary: </strong>The preliminary evidence summarized in this narrative review indicates that positive psychiatry interventions targeting social connectedness, meaning in life, wisdom, and resilience can improve overall well-being and other positive health outcomes amongst older adults. The effect sizes of these interventions reported in RCTs and meta-analyses are typically small to medium, but occasionally large effect sizes are also reported. Current literature is restricted by heterogeneous methodology, limiting clinicians' abilities to extrapolate these principles of positive psychiatry into everyday practice. With the expanding body of evidence, positive psychiatry may have the potential to transform the landscape of geriatric mental health.</p>","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 4","pages":"471-488"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904105/pdf/nihms-1624722.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25421424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Author Correction: Integrating Evidence-Based Guidelines on Pain and Opioids into Medical School Education","authors":"Jean M. Bennett, Barbara Allison-Bryan","doi":"10.1007/s40501-020-00235-7","DOIUrl":"https://doi.org/10.1007/s40501-020-00235-7","url":null,"abstract":"","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"8 1","pages":"29-30"},"PeriodicalIF":0.0,"publicationDate":"2020-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00235-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43734303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Simulation in Addiction Education","authors":"S. Jaeger, Brian S Fuehrlein","doi":"10.1007/s40501-020-00226-8","DOIUrl":"https://doi.org/10.1007/s40501-020-00226-8","url":null,"abstract":"","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 1","pages":"570 - 575"},"PeriodicalIF":0.0,"publicationDate":"2020-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00226-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45199277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Cornejo, H. McCready, Sarah Rabin, Shannon Boyce, Laura E. Dennis
{"title":"Clinical Off-Label Use of Deep Transcranial Magnetic Stimulation in Psychiatric Conditions","authors":"B. Cornejo, H. McCready, Sarah Rabin, Shannon Boyce, Laura E. Dennis","doi":"10.1007/s40501-020-00230-y","DOIUrl":"https://doi.org/10.1007/s40501-020-00230-y","url":null,"abstract":"","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 1","pages":"576 - 588"},"PeriodicalIF":0.0,"publicationDate":"2020-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00230-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45083256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of Opioid Use Disorder in the Elderly","authors":"Christine LaGrotta","doi":"10.1007/s40501-020-00231-x","DOIUrl":"https://doi.org/10.1007/s40501-020-00231-x","url":null,"abstract":"","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 1","pages":"531 - 543"},"PeriodicalIF":0.0,"publicationDate":"2020-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00231-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41735939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Patrick, Hannah L. Heintz, M. Skurla, B. Forester
{"title":"A Comprehensive Review of the Evaluation, Diagnosis, and Treatment of Older Adult Bipolar Disorder","authors":"R. Patrick, Hannah L. Heintz, M. Skurla, B. Forester","doi":"10.1007/s40501-020-00232-w","DOIUrl":"https://doi.org/10.1007/s40501-020-00232-w","url":null,"abstract":"","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 1","pages":"508 - 530"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00232-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41726276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sanne J H van Rooij, Patricio Riva-Posse, William M McDonald
{"title":"The Efficacy and Safety of Neuromodulation Treatments in Late-Life Depression.","authors":"Sanne J H van Rooij, Patricio Riva-Posse, William M McDonald","doi":"10.1007/s40501-020-00216-w","DOIUrl":"https://doi.org/10.1007/s40501-020-00216-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this review, the efficacy and safety of FDA approved neuromodulation devices (electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS)), as well as emerging neuromodulation treatments currently under investigation.</p><p><strong>Recent findings: </strong>ECT is the \"gold standard\" somatic therapy for treatment resistant depression (TRD). Although the clinical benefits are outweighed by potential cognitive and cardiovascular side effects in majority of cases, it remains unfairly stigmatized. TMS has few cognitive or somatic side effects but is not as effective the treatment of psychotic depression or more treatment resistant depression in elders. VNS has limited data in older patients but has been shown to be effective in chronic, treatment resistant adults. Several investigative neuromodulation treatments including magnetic seizure therapy (MST), focal electrically administered seizure therapy (FEAST), transcutaneous VNS (tVNS), transcranial direct current stimulation (tDCS), and deep brain simulation (DBS) shown promise in geriatric TRD.</p><p><strong>Summary: </strong>ECT, TMS and VNS are effective treatment for late-life depression, and research has continued to refine the techniques. Investigative neuromodulation techniques are promising, but evidence for the safety and efficacy of these devices in the geriatric population is needed.</p>","PeriodicalId":11088,"journal":{"name":"Current Treatment Options in Psychiatry","volume":"7 3","pages":"337-348"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40501-020-00216-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25371896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}